In 2022, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide, and 1.3 million people died. All this despite the availability of the BCG vaccine for infants.
The good news is that newer and better TB vaccines are on the horizon, and many are intended for use in adults and adolescents. Preventing disease in these age groups is predicted to have greatest impact on the global TB disease burden.
Join this GVIRF webinar to hear from experts across the TB vaccine community about the status of the TB vaccine pipeline, the challenges and opportunities in the field, and what is being done to prepare for success!
Free to join: register now at https://who.zoom.us/webinar/register/WN_B1qi05_KT9Om_EaGRhqGBg#/registration
Dear colleagues,
Please find below the GVIRF Webinar materials on New TB Vaccines for Adults and Adolescents, Progress, Prospects, and Perspectives.
- Video in English: https://www.youtube.com/watch?v=Otvm4schXwo
- Video in Spanish: https://youtu.be/SsUWmlIKS1A
- Video in French: https://youtu.be/J5f82KGguqs
- Presentation: https://www.technet-21.org/en/resources/presentation/global-vaccine-and-immunization-research-forum-webinar-new-tuberculosis-vaccines-for-adults-and-adolescents-progress-prospects-and-perspectives
For more GVIRF content, please go to the TechNet GVIRF page: https://www.technet-21.org/en/topics/global-initiatives/gvirf
- Page :
- 1